What is the recommended dose of budesonide (corticosteroid) via nebulizer for pediatric patients based on weight?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nebulized Budesonide Dosing for Pediatric Patients Based on Weight

For pediatric patients with asthma, the recommended dose of budesonide via nebulizer is 0.25-0.5 mg for low dose therapy and 0.5-1.0 mg for medium dose therapy, with up to 1.0-2.0 mg for high dose therapy, administered once or twice daily. 1

Dosing Guidelines by Age Group

Children Under 4 Years of Age

  • Low dose: 0.25-0.5 mg daily
  • Medium dose: 0.5-1.0 mg daily
  • High dose: >1.0 mg daily (up to 2.0 mg)

Children 4-11 Years of Age

  • Low dose: 0.5 mg daily
  • Medium dose: 1.0 mg daily
  • High dose: >1.0 mg daily (up to 2.0 mg)

Administration Considerations

  • Budesonide nebulizer suspension is the only inhaled corticosteroid with FDA-approved labeling for children <4 years of age 1
  • For children <4 years: Use a face mask that fits snugly over nose and mouth
  • Avoid nebulizing in the eyes
  • Wash face after each treatment to prevent local side effects
  • The dose may be administered once or twice daily
  • Use only jet nebulizers as ultrasonic nebulizers are ineffective for suspensions 1
  • Budesonide suspension is compatible with albuterol, ipratropium, and levalbuterol nebulizer solutions in the same nebulizer 1

Efficacy and Safety Considerations

  • For most patients, the ability to increase cortisol production in response to stress remains intact with budesonide inhalation suspension treatment at recommended doses 2
  • In studies of children 6 months to 8 years of age, the highest recommended dose of budesonide inhalation suspension (1 mg total daily dose) did not show statistically significant reduced urinary cortisol excretion compared to baseline 2
  • Once-daily administration of budesonide inhalation suspension has been shown to be effective and well-tolerated in children with mild persistent asthma 3

Important Clinical Considerations

  • Only about 14% of the nominal dose reaches infants and toddlers, with the percentage increasing from 9% to 19% with increasing age 4
  • Approximately 75% of the nominal dose remains in the nebulizer equipment 4
  • Despite this, the systemic exposure is similar across age groups, suggesting that from a safety perspective, the prescribed dose need not be adjusted for age 5

Potential Adverse Effects

  • Common side effects include cough, dysphonia, and oral thrush (candidiasis) 1
  • In high doses, systemic effects may occur, including adrenal suppression, although studies are not conclusive 1
  • In low-to-medium doses, suppression of growth velocity has been observed in children, but this effect may be transient 1
  • Monitor for HPA axis effects, especially in susceptible individuals, younger children, and patients given high doses for prolonged periods 2

Practical Tips

  • Use a spacer or valved holding chamber with non-breath-actuated MDIs
  • Have patients rinse mouth and spit after inhalation to decrease local side effects
  • For children using a face mask, clean the face after administration
  • The most important determinant of appropriate dosing is the clinician's judgment of the patient's response to therapy 1
  • Once control of asthma is achieved, the dose should be carefully titrated to the minimum dose required to maintain control 1

Remember that budesonide preparations are not interchangeable on a mcg or per-puff basis, and dosing should be adjusted based on clinical response.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1999

Research

How much nebulised budesonide reaches infants and toddlers?

Archives of disease in childhood, 1992

Research

Lung deposition of inhaled drugs increases with age.

American journal of respiratory and critical care medicine, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.